66 Early Experiences of the Use of Combination Immunotherapy for the Treatment of Malignant Mesothelioma from 2022 –2023 – Real-World Evidence of 1-Year Data from a Single UK Tertiary Cancer Centre
The landscape of systemic anticancer therapy (SACT) options for the treatment of malignant mesothelioma recently evolved following results from the CheckMate 743 trial which demonstrated improved overall survival in patients with malignant pleural mesothelioma receiving combination immunotherapy (Ipilimumab/ Nivolumab) in the first-line setting.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Justin KH Liu, Stephanie R Harrison, Dan Lee Tags: Mesothelioma Source Type: research
More News: Asbestosis | Cancer | Cancer & Oncology | Immunotherapy | Lung Cancer | Mesothelioma | Yervoy